Natural chemical drug production research institute

Production and research company of antioxidant product
(antioxidant dressing, macular degeneration treatment, cardiovascular treatment)

Division Zeaxanthin 9-cis β-carotene β-carotene
Product Pharmaceutical Raw Material for Macular Degeneration Treatment Atherosclerosis Treatment First-Aid Antioxidant Dressing & Burn Ointment
Characteristic Zeaxanthin is the material of Highly purified microalgae
The Highest Value among the purified products(Lutein, Meso-Zeaxanthin)
9-cis β-Carotene is discomposed into two substances, 9-cis Retinoid which break down fat cells in the blood and All-Trans-Retinoid that neutralize blood clotting by acting on the thrombus. Both of them have efficacy in the treatment of atherosclerosis. These products contain the Beta-carotene, which is extracted by first purification of microalgae, and it is coated with water-soluble Chitosan.
It solve the problems of conventional Liposoluble Vaseline gauze which is caused the skin absorption and secondary inflammation.
Market Value The market size of the macular degeneration is about USD 4billion in 2014 and CAGR 7.8%. It is estimated to reach USD 8billion by 2023. Cardio-cerebrovascular disease is #1 cause of death in the world
The global Atherosclerosis therapeutics market stood at $35 billion in 2012 and will grow at $45 billion by 2022.
Business Value The macular degeneration drugs in Korea are all import-dependent and most of the treatments contain about 25% Zeaxanthin.
We are in business agreement with Pharmaceutical Company ‘H’(No.1 Korea company in prescription medicine of Eye Drop domestic technology).
We are the only company related to Atherosclerosis therapeutics in Korea Bio-Venture and hold the patent about 9-cis β-Carotene purification process. Complete the certification evaluation by KCL (Korea Conformity Laboratories) Enable to produce from 2019.04
Enter the market to reduce initial marketing budget through military supply